Synapse - Martin Voss

Results (20)

A phase I dose-escalation and expansion study of telaglenastat in patients with advanced or metastatic solid tumors

Journal Article

Harding, J. J.; Telli, M.; Munster, P.; Voss, M. H.; Infante, J. R.; DeMichele, A.; Dunphy, M.; Le, M. H.; Molineaux, C.; Orford, K.; more...
Clinical Cancer Research (2021)

Fulltext@MSK | Save

Phase II clinical trial of everolimus in a pan-cancer cohort of patients with mTOR pathway alterations

Journal Article

Adib, E.; Klonowska, K.; Giannikou, K.; Do, K. T.; Pruitt-Thompson, S.; Bhushan, K.; Milstein, M. I.; Hedglin, J.; Kargus, K. E.; Sholl, L. M.; more...
Clinical Cancer Research (2021)

Fulltext@MSK | Save

First-in-humans trial of dasatinib-derivative tracer for tumor kinase-targeted PET

Journal Article

Krebs, S.; Veach, D. R.; Carter, L. M.; Grkovski, M.; Fornier, M.; Mauro, M. J.; Voss, M. H.; Danila, D. C.; Burnazi, E.; Null, M.; more...
Journal of Nuclear Medicine (2020)

Fulltext@MSK | Save

An evaluation of the role of tumor load in cytoreductive nephrectomy

Journal Article

Silagy, A. W.; Duzgol, C.; Marcon, J.; DiNatale, R. G.; Mano, R.; Blum, K. A.; Reznik, E.; Voss, M. H.; Motzer, R. J.; Coleman, J. A.; more...
CUAJ-Canadian Urological Association Journal (2020)

Fulltext@MSK | Save

Systemic therapy for advanced clear cell renal cell carcinoma after discontinuation of immune-oncology and VEGF targeted therapy combinations

Journal Article

Ged, Y.; Gupta, R.; Duzgol, C.; Knezevic, A.; Shapnik, N.; Kotecha, R.; Voss, M. H.; Feldman, D. R.; Akin, O.; Patil, S.; more...
BMC Urology (2020)

Fulltext@MSK | Save

The spinal distribution of metastatic renal cell carcinoma: Support for locoregional rather than arterial hematogenous mode of early bony dissemination

Meeting Abstract

Attalla, K.; Duzgol, C.; McLaughlin, L.; Flynn, J.; Ostrovnaya, I.; DiNatale, R. G.; Silagy, A. W.; Coleman, J.; Lee, C. H.; Carlo, M. I.; more...
Journal of Clinical Oncology (2020)

Fulltext@MSK | Save

Association of body mass index (BMI) with clinical outcomes in 203 metastatic clear cell renal cell carcinoma (ccRCC) patients (pts) treated with immuno-oncology (IO) agents

Meeting Abstract

Ged, Y.; Lee, C. H.; Sanchez, A.; Duzgol, C.; Chaim, J.; Carlo, M. I.; Foster, A.; Akin, O.; Feldman, D. R.; Hakimi, A. A.; more...
Journal of Clinical Oncology (2019)

Fulltext@MSK | Save

Systemic therapy for advanced clear cell renal cell carcinoma (ccRCC) after progression on immune-oncology plus VEGF targeted therapy combinations (IO-VEGF)

Meeting Abstract

Ged, Y.; Gupta, R.; Duzgol, C.; Shapnik, N.; Redzematovic, A.; Kotecha, R.; Voss, M. H.; Feldman, D. R.; Akin, O.; Patil, S.; more...
Journal of Clinical Oncology (2019)

Fulltext@MSK | Save

Tumor xenografts of human clear cell renal cell carcinoma but not corresponding cell lines recapitulate clinical response to sunitinib: Feasibility of using biopsy samples